TheStreet lowered shares of Kamada Ltd. (NASDAQ:KMDA) from a c- rating to a d+ rating in a report released on Tuesday.

Several other research analysts have also recently issued reports on KMDA. Jefferies Group LLC restated a buy rating and issued a $8.00 target price on shares of Kamada in a report on Wednesday, April 12th. Zacks Investment Research cut shares of Kamada from a hold rating to a strong sell rating in a report on Thursday, May 18th.

Kamada (KMDA) traded down 1.64% during mid-day trading on Tuesday, reaching $4.50. 186,411 shares of the company were exchanged. The company’s market capitalization is $163.89 million. Kamada has a 1-year low of $3.94 and a 1-year high of $8.61. The company has a 50 day moving average of $6.03 and a 200-day moving average of $6.72.

Kamada (NASDAQ:KMDA) last issued its earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.01. Kamada had a negative net margin of 2.24% and a negative return on equity of 2.97%. The business had revenue of $32.55 million during the quarter, compared to analysts’ expectations of $33.30 million. During the same quarter in the prior year, the business posted ($0.04) EPS. The company’s revenue for the quarter was up 70.7% on a year-over-year basis. On average, equities research analysts forecast that Kamada will post $0.06 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Kamada Ltd. (KMDA) Downgraded by TheStreet to D+” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at

Hedge funds have recently modified their holdings of the company. Edmond DE Rothschild Holding S.A. boosted its stake in shares of Kamada by 17.8% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 38,200 shares of the biotechnology company’s stock worth $266,000 after buying an additional 5,772 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Kamada by 16.7% in the first quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock worth $1,801,000 after buying an additional 37,800 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Kamada during the first quarter worth $575,000. Finally, Norges Bank acquired a new stake in shares of Kamada during the fourth quarter worth $377,000. Hedge funds and other institutional investors own 5.69% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Receive News & Stock Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related stocks with our FREE daily email newsletter.